Ligand id: 8281

Name: treosulfan

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: treosulfan

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 143.96
Molecular weight 278.01
XLogP -3.29
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
The EMA has granted treosulfan orphan drug status to be used as a conditioning treatment prior to haematopoietic progenitor cell transplantation. The FDA has granted orphan drug status for the treatment of ovarian cancer. Four Phase III clinical trials assessing treosulfan as a conditioning treatment are ongoing, as are Phase III studies for ovarian cancer and Ewing's sarcoma.
Mechanism Of Action and Pharmacodynamic Effects
As a DNA alkylating (cross-linking) agent, treosulfan treatment irreversibly interferes with DNA replication, RNA transcription and causes general disruption of nucleic acid function. This action causes cell death.